Skip to main content

Table 2 Total PRISM score according to treatment group, evaluation moment and phase of the menstrual cycle

From: Essential fatty acids for premenstrual syndrome and their effect on prolactin and total cholesterol levels: a randomized, double blind, placebo-controlled study

Period Treatment Groups Difference between groups p-value*
  A (1 g) B (2 g) C (Placebo)  
  Median (P25 - P75) Median (P25 - P75) Median (P25 - P75)  
Pretreatment     
Follicular 29 (19 - 63) 27 (17 - 37) 28.5 (19 - 33) A X B: 0.2629
Luteal 99 (87 - 162) 98 (82 - 123) 96.5 (89 - 117) A X C: 0.3130
Difference 77 (61 - 94) 73 (51 - 84) 74 (49 - 88) B X C: 0.9878
p-valueΔ < 0.001 < 0.001 < 0.001  
3 months     
Follicular 17 (11 - 38) 21 (15 - 25) 25.5 (18 - 31) A X B: 0.0017
Luteal 58 (42 - 79) 48 (41 - 61) 88.5 (78 - 109) A X C: 0.0001
Difference 41 (26 - 50) 27 (20 - 34) 63.5 (48 - 79) B X C: <0.001
p-valueΔ < 0.001 < 0.001 < 0.001  
6 months     
Follicular 08 (05 - 28) 09 (07 - 12) 25 (16 - 31) A X B: 0.0029
Luteal 35 (31 - 56) 28 (24 - 35) 89 (74 - 105) A X C: <0.001
Difference 27 (18 - 33) 18 (12 - 23) 62 (41 - 75) B X C: <0.001
p-valueΔ < 0.001 < 0.001 < 0.001  
  1. Δ Comparison of the PRISM scores between the follicular and luteal phases (Wilcoxon's signed-rank test) within each treatment group.
  2. * Comparison of the difference in PRISM score between the follicular and luteal phases among the three groups (Mann-Whitney test).
  3. P25: 1st quartile
  4. P75: 3rd quartile